Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscular Recombinant 9-Valent Human Papillomavirus (9vHPV) Vaccine in Subjects Aged greater than or equal to 9 to less than 15 Years in an Endemic Country for Dengue

Next Previous
Search
Trial Profile

A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscular Recombinant 9-Valent Human Papillomavirus (9vHPV) Vaccine in Subjects Aged greater than or equal to 9 to less than 15 Years in an Endemic Country for Dengue

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dengue tetravalent vaccine Takeda (Primary) ; V 503 (Primary)
  • Indications Dengue
  • Focus Pharmacodynamics; Registrational
  • Sponsors Takeda

    • Most Recent Events

    • 26 Dec 2022 New source identified an integrated (European Clinical Trials Database; EudraCT2022-003339-24).
    • 20 Jul 2022 Status changed from active, no longer recruiting to completed.
    • 28 Oct 2021 Planned End Date changed from 25 Jul 2022 to 4 Jul 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top